Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT).

Trial Profile

Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2016

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Glucose intolerance; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms J-PREDICT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2015 Results of a subanalysis in lean patients with impaired glucose tolerance presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 19 Sep 2014 Post-hoc analysis results were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top